Literature DB >> 19328453

Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." Prevention trials in persons at risk for dominantly inherited Alzheimer's disease: opportunities and challenges.

John M Ringman1, Joshua Grill, Yaneth Rodriguez-Agudelo, Mireya Chavez, Chengjie Xiong.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19328453      PMCID： PMC2746429          DOI： 10.1016/j.jalz.2008.12.002

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN： 1552-5260            Impact factor:   21.566


× No keyword cloud information.
  27 in total

1.  The A431E mutation in PSEN1 causing familial Alzheimer's disease originating in Jalisco State, Mexico: an additional fifteen families.

Authors:  Jill Murrell; Bernardino Ghetti; Elizabeth Cochran; Miguel Angel Macias-Islas; Luis Medina; Arousiak Varpetian; Jeffrey L Cummings; Mario F Mendez; Claudia Kawas; Helena Chui; John M Ringman
Journal:  Neurogenetics       Date:  2006-08-05       Impact factor: 2.660

2.  Statins differentially affect amyloid precursor protein metabolism in presymptomatic PS1 and non-PS1 subjects.

Authors:  Douglas A Hinerfeld; Majaz Moonis; Joan M Swearer; Stephen P Baker; Richard J Caselli; Ekaterina Rogaeva; Peter St George-Hyslop; Daniel A Pollen
Journal:  Arch Neurol       Date:  2007-11

3.  Impact of DNA testing for early-onset familial Alzheimer disease and frontotemporal dementia.

Authors:  E J Steinbart; C O Smith; P Poorkaj; T D Bird
Journal:  Arch Neurol       Date:  2001-11

4.  Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations.

Authors:  Eva Czirr; Stefanie Leuchtenberger; Cornelia Dorner-Ciossek; Anna Schneider; Mathias Jucker; Edward H Koo; Claus U Pietrzik; Karlheinz Baumann; Sascha Weggen
Journal:  J Biol Chem       Date:  2007-06-15       Impact factor: 5.157

Review 5.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

6.  Biochemical markers in persons with preclinical familial Alzheimer disease.

Authors:  J M Ringman; S G Younkin; D Pratico; W Seltzer; G M Cole; D H Geschwind; Y Rodriguez-Agudelo; B Schaffer; J Fein; S Sokolow; E R Rosario; K H Gylys; A Varpetian; L D Medina; J L Cummings
Journal:  Neurology       Date:  2008-05-28       Impact factor: 9.910

7.  Optimizing phase II of drug development for disease-modifying compounds.

Authors:  Jeffrey L Cummings
Journal:  Alzheimers Dement       Date:  2008-01       Impact factor: 21.566

8.  Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations.

Authors:  John M Ringman; Joseph O'Neill; Daniel Geschwind; Luis Medina; Liana G Apostolova; Yaneth Rodriguez; Barbara Schaffer; Arousiak Varpetian; Benjamin Tseng; Freddy Ortiz; Jaime Fitten; Jeffrey L Cummings; George Bartzokis
Journal:  Brain       Date:  2007-05-23       Impact factor: 13.501

Review 9.  Disease-modifying therapies for Alzheimer disease: challenges to early intervention.

Authors:  Jeffrey L Cummings; Rachelle Doody; Christopher Clark
Journal:  Neurology       Date:  2007-10-16       Impact factor: 9.910

10.  Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study.

Authors:  Basil H Ridha; Josephine Barnes; Jonathan W Bartlett; Alison Godbolt; Tracey Pepple; Martin N Rossor; Nick C Fox
Journal:  Lancet Neurol       Date:  2006-10       Impact factor: 44.182
View more
  13 in total

Review 1.  Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial.

Authors:  S M Mills; J Mallmann; A M Santacruz; A Fuqua; M Carril; P S Aisen; M C Althage; S Belyew; T L Benzinger; W S Brooks; V D Buckles; N J Cairns; D Clifford; A Danek; A M Fagan; M Farlow; N Fox; B Ghetti; A M Goate; D Heinrichs; R Hornbeck; C Jack; M Jucker; W E Klunk; D S Marcus; R N Martins; C M Masters; R Mayeux; E McDade; J C Morris; A Oliver; J M Ringman; M N Rossor; S Salloway; P R Schofield; J Snider; P Snyder; R A Sperling; C Stewart; R G Thomas; C Xiong; R J Bateman
Journal:  Rev Neurol (Paris)       Date:  2013-09-06       Impact factor: 2.607

2.  Optimum Design of Disease-modifying Trials on Alzheimer's Disease.

Authors:  Chengjie Xiong; Jingqin Luo; Feng Gao; Ling Chen; Yan Yan
Journal:  Stat Biopharm Res       Date:  2012-08-30       Impact factor: 1.452

3.  Optimizing parameters in clinical trials with a randomized start or withdrawal design.

Authors:  Chengjie Xiong; Jingqin Luo; Feng Gao; John C Morris
Journal:  Comput Stat Data Anal       Date:  2014-01-01       Impact factor: 1.681

4.  Subsets of a large cognitive battery better power clinical trials on early stage Alzheimer's disease.

Authors:  Chengjie Xiong; Hua Weng; David A Bennett; Patricia A Boyle; Raj C Shah; Scot Fague; Charles B Hall; Richard B Lipton; John C Morris
Journal:  Neuroepidemiology       Date:  2014-11-05       Impact factor: 3.282

5.  Designing clinical trials to test disease-modifying agents: application to the treatment trials of Alzheimer's disease.

Authors:  Chengjie Xiong; Gerald van Belle; J Philip Miller; John C Morris
Journal:  Clin Trials       Date:  2011-02       Impact factor: 2.486

6.  Linear Combinations of Multiple Outcome Measures to Improve the Power of Efficacy Analysis ---Application to Clinical Trials on Early Stage Alzheimer Disease.

Authors:  Chengjie Xiong; Jingqin Luo; John C Morris; Randall Bateman
Journal:  Biostat Epidemiol       Date:  2017-06-02

7.  Combining Multiple Markers to Improve the Longitudinal Rate of Progression-Application to Clinical Trials on the Early Stage of Alzheimer's Disease.

Authors:  Chengjie Xiong; Gerald van Belle; Kewei Chen; Lili Tian; Jingqin Luo; Feng Gao; Yan Yan; Ling Chen; John C Morris; Paul Crane
Journal:  Stat Biopharm Res       Date:  2013-01-01       Impact factor: 1.452

8.  The impact of the availability of prevention studies on the desire to undergo predictive testing in persons at risk for autosomal dominant Alzheimer's disease.

Authors:  Megan Hooper; Joshua D Grill; Yaneth Rodriguez-Agudelo; Luis D Medina; Michelle Fox; Ana Isabel Alvarez-Retuerto; David Wharton; Jenny Brook; John M Ringman
Journal:  Contemp Clin Trials       Date:  2013-07-19       Impact factor: 2.226

9.  Minimizing the Sample Sizes of Clinical Trials on Preclinical and Early Symptomatic Stage of Alzheimer Disease.

Authors:  J Luo; H Weng; J C Morris; C Xiong
Journal:  J Prev Alzheimers Dis       Date:  2018

10.  A novel PSEN1 (S230N) mutation causing early-onset Alzheimer's Disease associated with prosopagnosia, hoarding, and Parkinsonism.

Authors:  John M Ringman; Maria Casado; Victoria Van Berlo; Judy Pa; Nelly Joseph-Mathurin; Anne M Fagan; Tammie Benzinger; Randall J Bateman; John C Morris
Journal:  Neurosci Lett       Date:  2017-07-29       Impact factor: 3.197
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.